NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

A team led by the Institute for Bioengineering of Catalonia (IBEC) and the Hospital del Mar Research Institute has developed ...

CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...

Becky Kamowitz was appointed executive director of The Skin Cancer Foundation in January 2025. She talks about the ...

A university building evacuated, a hapless driver rescued, shipping paused, and thousands without power as emergency and utility crews work around the clock responding to countless calls for help.

Nintendo has finally revealed its new console, Nintendo Switch 2, and we’ve published the first images in a gallery below. In a Nintendo Switch 2 reveal video published on Thursday, the platform ...

Trump later seized on what appeared at the time to be a good-natured exchange to promote his “Fight, Fight, Fight” line of colognes. He shared a photo of himself and Biden on social media alongside ...

The fires continue to burn, and the full extent of the damage is still unknown. These latest photos show what's left of places thousands of people call home: What caused the massive blaze in ...

The filmmaker possessed a singular vision — and a knack for finding collaborators who could convey it. The filmmaker possessed a singular vision — and a knack for finding collaborators who ...

Nintendo has finally lifted the lid on Switch 2 and... well, it looks an awful lot like the Switch. But there are subtle differences, a few obvious new additions, and still some intriguing ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...